文献速递肝病

早期置入经颈静脉肝内门体分流术治疗复发性腹水的成本效益分析

Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-30

研究采用马尔可夫模型,从支付方视角比较早期经颈静脉肝内门体分流术(TIPS)与连续大量腹腔穿刺放液加白蛋白输注(LVP+A)治疗肝硬化复发性腹水的成本效益。基础分析显示早期TIPS成本更高(22770美元 vs 19180美元)但QALY更高(0.73 vs 0.65),ICER为46310美元/QALY。概率敏感性分析中TIPS在59.1%的模拟中为最优策略,作者认为早期TIPS对特定患者具有成本效益,应考虑作为一线治疗选择。

要点

  • 早期TIPS较LVP+A成本更高(22770美元 vs 19180美元)但QALY更高(0.73 vs 0.65)。
  • 基础分析ICER为46310美元/QALY,低于100000美元/QALY的成本效益阈值。
  • 概率敏感性分析中TIPS置入在59.1%的模拟中为最优策略。

核心结论

  • 基于马尔可夫模型分析,早期置入TIPS似乎是对特定肝硬化复发性腹水患者具有成本效益的策略。
  • 作者认为对特定患者应早期考虑TIPS置入并作为一线治疗选择。

研究设计与样本

  • 研究采用马尔可夫模型,从支付方视角对肝硬化复发性腹水患者进行假设队列分析。
  • 模型数据来源于2012年至2018年收集的出版物和国家数据库。
  • 比较策略为早期TIPS置入与连续大量腹腔穿刺放液加白蛋白输注(LVP+A)。
  • 早期TIPS定义为过去3周内2次LVP且过去3个月内少于6次LVP。
  • 进行了单因素、双因素和概率敏感性分析,ICER低于100000美元/QALY被视为具有成本效益。

主要发现

  • 基础分析中早期TIPS成本为22770美元,高于LVP+A的19180美元。
  • 早期TIPS的QALY为0.73,高于LVP+A的0.65。
  • 基础分析ICER为46310美元/QALY。
  • 结果对无并发症TIPS置入和移植成本、LVP+A需求、移植概率和失代偿QALY敏感。
  • 概率敏感性分析中TIPS置入在59.1%的模拟中为最优策略。

关键数值与推荐

  • ICER低于100000美元/QALY被视为具有成本效益。
  • 早期TIPS定义为过去3周内2次LVP且过去3个月内少于6次LVP。

临床怎么用

  • 作者认为对特定肝硬化复发性腹水患者应早期考虑TIPS置入并作为一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Treatment options for recurrent ascites resulting from decompensated cirrhosis include serial large-volume paracentesis and albumin infusion (LVP+A) or insertion of a transjugular intrahepatic portosystemic shunt (TIPS). Insertion of TIPSs with covered stents during early stages of ascites (early TIPS, defined as 2 LVPs within the past 3 weeks and <6 LVPs in the prior 3 months) significantly improves chances of survival and reduces complications of cirrhosis compared with LVP+A. However, it is not clear if TIPS insertion is cost effective in these patients. METHODS: We developed a Markov model using the payer perspective for a hypothetical cohort of patients with cirrhosis with recurrent ascites receiving early TIPSs or LVP+A using data from publications and national databases collected from 2012 to 2018. Projected outcomes included quality-adjusted life-year (QALY), costs (2017 US dollars), and incremental cost-effectiveness ratios (ICERs; $/QALY). Sensitivity analyses (1-way, 2-way, and probabilistic) were conducted. ICERs less than $100,000 per QALY were considered cost effective. RESULTS: In base-case analysis, early insertion of TIPS had a higher cost ($22,770) than LVP+A ($19,180), but also increased QALY (0.73 for early TIPSs and 0.65 for LVP+A), resulting in an ICER of $46,310/QALY. Results were sensitive to cost of uncomplicated TIPS insertion and transplant, need for LVP+A, probability of transplant, and decompensated QALY. In probabilistic sensitivity analysis, TIPS insertion was the optimal strategy in 59.1% of simulations. CONCLUSIONS: Based on Markov model analysis, early placement of TIPSs appears to be a cost-effective strategy for management of specific patients with cirrhosis and recurrent ascites. TIPS placement should be considered early and as a first-line treatment option for select patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shen NT, Schneider Y, Congly SE, et al. Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. Clin Gastroenterol Hepatol. 2018. PMID: 29609068. doi:10.1016/j.cgh.2018.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。